Overview

A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy Subjects

Status:
Completed

Trial end date:
2019-03-22

Target enrollment:

Participant gender:

Summary

This study is a phase 1, double-blind, placebo-controlled crossover study of SAGE-718 using a ketamine challenge, to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic response using magnetic resonance imaging in healthy subjects

Phase:

Phase 1

Details

Lead Sponsor:

Sage Therapeutics

Treatments:

Ketamine